Background: An objective measure is needed to identify frail older adults with cancer who are at increased risk for poor health outcomes. The primary objective of this study was to develop a frailty index from a cancer-specific geriatric assessment (GA) and evaluate its ability to predict all-cause mortality among older adults with cancer. Patients and Methods: Using a unique and novel data set that brings together GA data with cancer-specific and long-term mortality data, we developed the Carolina Frailty Index (CFI) from a cancer-specific GA based on the principles of deficit accumulation. CFI scores (range, 0-1) were categorized as robust (0-0.2), pre-frail (0.2-0.35), and frail (>0.35). The primary outcome for evaluating predictive validity was all-cause mortality. The Kaplan-Meier method and log-rank tests were used to compare survival between frailty groups, and Cox proportional hazards regression models were used to evaluate associations. Results: In our sample of 546 older adults with cancer, the median age was 72 years, 72% were women, 85% were white, and 47% had a breast cancer diagnosis. Overall, 58% of patients were robust, 24% were pre-frail, and 18% were frail. The estimated 5-year survival rate was 72% in robust patients, 58% in pre-frail patients, and 34% in frail patients (log-rank test, P<.0001). Frail patients had more than a 2-fold increased risk of all-cause mortality compared with robust patients (adjusted hazard ratio, 2.36; 95% CI, 1.51-3.68). Conclusions: The CFI was predictive of all-cause mortality in older adults with cancer, a finding that was independent of age, sex, cancer type and stage, and number of medical comorbidities. The CFI has the potential to become a tool that oncologists can use to objectively identify frailty in older adults with cancer.
Background
Frailty is a geriatric syndrome that identifies vulnerable older adults who are at increased risk for hospitalization, institutionalization, and death. [1] [2] [3] [4] [5] These adverse
From the a Therefore, identifying frail older adults with cancer is critical to individualizing treatment decisions and minimizing poor health outcomes. 7 The health and functional status of older adults with cancer varies widely, independent of chronologic age, and standard performance status measures do not provide an accurate estimation of functional age or likely frailty status. [7] [8] [9] As the incidence of cancer in older adults is expected to increase rapidly, 10 the importance of having a standardized, valid, and practical definition of oncologic frailty has never been more imperative. This definition is needed before frailty classification can help guide treatment decisions.
In the geriatric literature, there are 2 commonly accepted and validated clinical models of frailty. The first, the phenotype model of frailty, developed from a secondary analysis of the Cardiovascular Health Study, incorporates 5 criteria: unintentional weight loss, weakness measured by grip strength using a handheld dynamometer, self-reported exhaustion, slow gait speed, and low physical activity. 3 With this model, a patient is considered frail if they meet ≥3 of these criteria. The second model, the deficit accumulation model of frailty, identifies the total number of health deficits (ie, symptoms, signs, disabilities, diseases, abnormal laboratory values) a person has, with an increasing number of health deficits indicating greater frailty. 11 This method is pragmatic because it relies less on information from any one health deficit and has minimal restrictions on which health deficits are included in the model, provided the deficits cover a range of geriatric domains and syndromes. 12 Both clinical models of frailty have been shown to be associated with poor health outcomes in the general older adult population and to overlap in their ability to identify frailty. [1] [2] [3] 13, 14 The cancer-specific geriatric assessment (GA) 15 is a multidimensional assessment that combines patientreported and healthcare provider-administered questionnaires to evaluate geriatric domains and is recommended for every older adult with cancer. 16, 17 The cancer-specific GA is known to identify deficits in patients with a normal Karnofsky performance status and is predictive of treatment-related toxicity in older adults with solid tumors. 9, 18, 19 The GA is widely used in geriatric oncology research; however, it has had limited uptake among oncologists in clinical practice. The primary objective of this study was to develop a practical frailty index using a cancer-specific GA based on the principles of deficit accumulation and to evaluate its ability to predict all-cause mortality among older adults with cancer.
Patients and Methods

Sample
The Carolina Senior: UNC Registry for Older Patients (CSR) is an institutional database that contains cross-sectional GA data from older adults (age ≥65 years) with cancer (ClinicalTrials.gov identifier: NCT01137825). The CSR recruits patients diagnosed with any cancer type and at any phase of cancer care (newly diagnosed before treatment, during treatment, after treatment). The cancer-specific GA used in the CSR has been proven feasible in the academic, community, and cooperative group settings. 15, 20, 21 This GA contains valid and reliable measures of geriatric domains, including instrumental activities of daily living (IADLs), physical function, number of medications, comorbidities, nutritional status, mental health, social activity and support, and cognitive function. 15 The CSR began enrolling patients in 2009, and informed consent was obtained for each participant before completing a one-time GA. For this study, patients enrolled in the CSR from 2009 to 2014 from the North Carolina Cancer Hospital, a large academic medical center, were linked to the North Carolina Central Cancer Registry (NCCCR) to obtain tumor-specific data and vital status. The Institutional Review Board of the University of North Carolina separately approved the CSR and data linkage including this frailty data analysis.
Cancer Characteristics
The NCCCR collects data on all cancers diagnosed in North Carolina. Tumor-specific data (through 2013) and all-cause and cancer-specific mortality (through August 2015) were obtained from NCCCR. Cancer type was obtained using the International Classification of Diseases for Oncology (ICD-O) codes and collapsed into broader cancer categories (eg, breast, lung, gastrointestinal). The date of cancer diagnosis and staging information according to the AJCC 6th Edition was also obtained.
Frailty Measure
We developed the Carolina Frailty Index (CFI) using the CSR cancer-specific GA based on the principles of deficit accumulation originally described by Rockwood et al. 1 Our framework for creating the frailty index from CSR data was previously described by Searle et al. 12 To create our CFI, we selected variables from the GA that were generally known to be associated with health status and that increased in frequency with aging. In addition, as previously reported by Searle et al, 12 variables in the frailty index need to cover multiple geriatric domains, and the index needs to include 30 to 40 variables to accurately predict outcomes of clinical interest. Using this methodology, we identified 36 variables from the GA for our CFI, with a focus on patient-reported single-item questions concerning IADLs, physical function, comorbidities, number of daily medications, vision, hearing, nutrition, mental health, and social activity. 15 In addition, we included an objective measure of physical function (Timed Up and Go test) 22 and cognition (Blessed Orientation-MemoryConcentration test), 23 originally assessed by a trained clinical research assistant. Each variable in the CFI was scored from 0 to 1, with a higher score indicating the presence of a health deficit (Table 1) .
Participants who reported <18 of the 36 variables in the CFI (n=7; 1%) were excluded from this analysis. Of the remaining 546 patients, 96% reported >32 variables. Scores were calculated by summing the number of positive responses and dividing by the total number of items completed to obtain a final score between 0 and 1. For patients with missing variables, the total number of variables completed was used as the denominator. CFI scores were categorized as robust (0-0.2), pre-frail (0.2-0.35), and frail (>0.35).
Primary Outcome
The primary outcome for the predictive validity analysis was all-cause mortality assessed after the date of GA completion. The NCCCR obtains mortality data through annual linking to the National Death Index, Social Security Death Index, and North Carolina State Center for Vital Statistics using name, date of birth, and social security number. As a secondary outcome, we also evaluated the CFI's ability to predict cancer-specific mortality, recorded as the primary cause of death on the state death certificate.
Statistical Analysis
Descriptive statistics are provided in Table 2 for the entire sample and subdivided by frailty status type, 29% of patients with lung and bronchus cancers, 23% of those with hematologic malignancies, and 14% of those with breast cancer were categorized as frail. For race, 28% of nonwhite patients were categorized as frail compared with 16% of white patients. Importantly, cancer stage was not significantly associated with frailty (P=.13).
Frailty and Mortality
In our sample of 546 patients, 191 deaths (35%) were observed from any cause, among which 143 (26%) were cancer-related. Median follow-up of the cohort was 3.7 years (range, 0.9-5.7 years). Median OS in patients categorized as frail was 1.6 years (95% CI, 1.14-3.22). Median OS in those categorized as prefrail or robust was not met at the time of this analysis. The estimated 5-year OS was 72% (95% CI, 66%-77%) in robust patients, 58% (95% CI, 48%-66%) in pre-frail patients, and 34% (95% CI, 24%-45%) in frail patients (P≤.0001; Figure 2A ). The estimated cancer-specific survival rate at 5 years was 77% (95% CI, 72%-82%) for robust patients, 68% (95% CI, 59%-76%) for pre-frail patients, and 54% (95% CI, 42%-64%) for frail patients (P≤.0001). When evaluating the CFI's ability to predict allcause mortality in patients who completed the GA within 90 days of their diagnosis (N=179; incident cancer group), the log-rank test for differences in all-cause mortality between frailty groups remained significant (P=.001; Figure 2B ). The results of a sensitivity analyses limited to patients with no missing variables on the 36-item CFI resulted in similar findings (data not shown). Table 3 reports the associations between frailty groups and all-cause mortality based on the CFI for (1) all patients and (2) the incident cancer group. There was a strong relationship observed between increasing frailty and all-cause mortality when measured by the CFI. The unadjusted hazard ratios (HRs) show that patients categorized as frail had more than a 3-fold increased risk of all-cause mortality (HR, 3.34; 95% CI, 2.39-4.69) compared with those classified as robust. After adjusting for age, sex, cancer type and stage, and number of medical comorbidities, the patients categorized as frail by the CFI had a significantly higher hazard of death compared with robust patients (adjusted HR, 2.36; 95% CI, 1.51-3.68). The incident cancer group analysis yielded similar results to the entire cohort, with an adjusted HR of 1.98 (95% (robust, pre-frail, and frail). In addition to evaluating the entire cohort, we also preplanned a subgroup analysis to evaluate patients who completed the GA within 90 days of their cancer diagnosis (incident cancer group). Differences between frailty groups were evaluated using analysis of variance for age and chi-square tests for categorical measures. The Kaplan-Meier method was used to estimate overall survival (OS) and cancer-specific survival from the date of GA completion, and log-rank tests were used to compare survival between frailty groups. A sensitivity analysis was completed to evaluate the relationship of the CFI with all-cause mortality only for those patients with no missing data. Multivariable Cox proportional hazards regression models were used to evaluate the association between frailty and all-cause mortality after controlling for covariates of age, sex, cancer stage and type, and number of medical comorbidities. All analyses were conducted using SAS v9.4 statistical software (Cary, NC).
Results
Patient Characteristics
From 2009 to 2014, the CSR enrolled 703 patients from the North Carolina Cancer Hospital who completed the GA. Of those patients, 636 were matched to NCCCR using name, date of birth, and sex (90% match rate), of which 553 patients had adequate tumor-specific and survival data; 7 patients were excluded because of missing data, leaving an analytic cohort of 546 patients.
Among the 546 patients (Table 2) , the median age was 72 years at the time of the GA (range, 65-100 years). Most patients were female (n=393; 72%), white (n=463; 85%), had a breast cancer diagnosis (n=257; 47%), had stage 0-II disease (n=295; 54%), and had at least a high school education (n=506; 92%); 179 patients (33%) completed the GA within 90 days of their date of diagnosis (incident cancer group).
Frailty
Using the 36-item CFI, 58% of patients (N=318) were categorized as robust, 24% (N=131) as pre-frail, and 18% (N=97) as frail (Figure 1 ). Increasing age (P≤.001), nonwhite race (P=.02), lowwer education (P≤.001), and cancer type (P=.002) were associated with increasing levels of frailty (Table 2 ). For cancer (38) 151 (73) 39 (19) 18 (9) 70-74 155 (28) 93 (60) 36 (23) 26 (17) 75-79 91 (17) 44 (48) 26 (29) 21 (23) ≥80 92 (17) 30 (33) 30 (33) 32 (35) Sex Female 393 (72) 233 (59) 90 (23) 70 (18) .62 Male 153 (28) 85 (55) 41 (27) 27 (18) Race White 463 (85) 279 (60) 110 (24) 74 (16) .02 Other 83 (15) 39 (47) 21 (25) 23 (28) Cancer type Breast 257 (47) 173 (67) 48 (19) 36 (14) .002
Lung and bronchus 66 (12) 31 (47) 16 (24) 19 (29) Hematologic malignancy 66 (12) 29 (44) 22 (33) 15 (23) Gastrointestinal 41 (8) Time from diagnosis to complete GA ≤90 days 179 (33) 112 (63) 33 (18) 34 (19) .51 91 days to 1 year 120 (22) 64 (53) 33 (28) 23 (19) 1-3 years 108 (20) 63 (58) 28 (26) 17 (16) >3 years 139 (25) 79 (57) 37 (27) 23 (17) Educational level
High school graduate or less 267 (49) 129 (48) 78 (29) 60 (22) <.001 Associate/Bachelor's degree 150 (28) 102 (68) 27 (18) 21 (14) Advanced degree 126 (23) 85 (67) 26 (20) 15 (12) Abbreviation: GA, geriatric assessment. *Cells combined with cell below to preserve confidentiality.
CI, 0.99-3.94) of death for frail compared with robust patients. When evaluating cancer-specific mortality for all patients, a strong relationship remained between increasing frailty and cancer-specific mortality, with an adjusted HR of 2.00 (95% CI, 1.20-3.33) for frail compared with robust patients.
Discussion
In our sample of older adults with cancer, the CFI developed from a cancer-specific GA was predictive of all-cause mortality in all patients, and remained predictive in those who completed the GA within 90 days of their cancer diagnosis (incident cancer group). In addition, frailty was also predictive of cancer-specific mortality for the entire cohort. Frail patients had more than a 2-fold increased risk of all-cause mortality compared with robust patients, a finding that was independent of age, sex, cancer type and stage, and number of medical comorbidities. The CFI is an objective measure of frailty, a geriatric syndrome known to increase the risk of hospitalization, institutionalization, and death. [1] [2] [3] [4] [5] It is important for oncologists to identify frail patients at risk for poor health outcomes, because cancer therapy may increase the risk of developing frailty and Years From GA
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disability. 24 In addition, frailty markers have been shown to be associated with poor treatment tolerance and toxicity in older adults with cancer. 25, 26 A recent study by the Cancer and Aging Research Group showed that frail and pre-frail patients with solid tumors were more likely to have grade 3 chemotherapy-related toxicity, discontinue treatment, and become hospitalized. This study used a 51-item frailty index, which, in addition to GA variables, included laboratory values and demographics. 27 The CFI, a shorter, nearly all patient-reported frailty index, may better fit the needs of a busy clinical practice for oncologists to objectively identify frailty in older adults with cancer. With the move to electronic medical records across health systems, ideally the CFI-after further validations studies are completed-would be in the form of an electronic tool that captures and analyzes the data in real time.
A recent systematic review in oncology reported that the prevalence of frailty varied considerably in older adults with cancer, ranging widely from 6% to 86% depending on the definition of frailty that was used and the population that was studied. 28 In the review, the phenotype model of frailty or the presence of 2 to 3 GA domain impairments were the most commonly used definitions of frailty. 28 However, a notable gap remained-only a few studies included in the review reported on the relationship between frailty and outcomes. 25, 26, [29] [30] [31] [32] In older women with breast cancer, having geriatric domain impairments was associated with poor tolerance to treatment, allcause mortality, and breast cancer-specific survival at 10 years. 25, 29 Several studies from the surgical oncology literature have used different frailty assessment tools to predict 30-day postoperative morbidity and/or mortality. [30] [31] [32] [33] [34] [35] [36] [37] The deficit accumulation model of frailty has not been extensively studied in older adults with cancer and has several clinical practice advantages over the phenotype model. Specifically, the deficit accumulation model of frailty does not require special instrumentation (eg, handheld dynamometers) to complete, nor does it rely on a research-oriented questionnaire. The CFI, constructed from the most widely used and tested cancer-specific GA, 15 is a practical method for defining oncologic frailty, and this study provides evidence for a validated clinical model of frailty specific to older adults with cancer.
Our study has limitations. Most patients in the CSR have early-stage cancers and most have a breast cancer diagnosis. This may limit the generalizability of our CFI to the broader spectrum of cancer types and stages. More validation is warranted in other cancer populations. Even though our sample consisted largely of patients with breast cancer, the percentage of patients who were frail was similar to what has been reported in the older adult community (14%). 38 In addition, findings from our study may not be generalizable due to the lack of sociodemographic diversity. Our study also has important strengths. The combined CSR-NCCCR is a unique and novel data set that brings together detailed information from a cancer-specific GA, which allows for construction of the frailty index, with cancer-specific and long-term mortality data. This data linkage allows for passive, long-term follow-up of clinical outcomes.
The use of the GA and frailty measures to individualize treatment decisions is of great interest. The CFI may have utility in the future to design GAbased treatment trials after further validation studies are completed. The CFI may also provide a better measure of performance status than traditional measures currently used in clinical trials, 8 because age or standard performance status measures do not provide an accurate estimation of functional age. [7] [8] [9] The CFI also provides an overall scoring system for the GA that can be easily and quickly interpreted.
Conclusions
Our study provides the first step in validating a clinical model of frailty for older adults with cancer. The term "frail older adult with cancer" is commonly used, and having an objective definition of this physiologic state is critical to operationalizing the term. The CFI constructed from a cancer-specific GA was predictive of all-cause and cancer-specific mortality in a heterogeneous group of older adults with cancer. Further validation and investigation is warranted by cancer type and stage before it can be more widely applied across cancer populations. The CFI is a practical way to define oncologic frailty and has the potential to be used with ease in busy clinics to help oncologists personalize treatment decisions for older adults and identifying subgroups that may benefit from targeted frailty interventions.
